Mitsubishi Electric to Increase Stake in Realtime Robotics to Support Expanded Use of Motion-planning Technology in FA Products

Must Read

TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation (TOKYO:6503) announced today that it will increase its existing investment in Massachusetts-based Realtime Robotics, Inc., an American startup company that is pioneering motion-planning technology for calculating trajectories to enable factory-automation (FA) equipment to avoid obstacles and generate optimized routes.


By expanding the use of Realtime Robotics’ advanced technology in Mitsubishi Electric’s FA solution software products and control-system equipment, the partners expect to further enhance the digitalization and optimization of automated production at manufacturing sites. Since May 2019, when Mitsubishi Electric first invested in Realtime Robotics, the two companies have been promoting technological collaboration between Realtime’s motion-planning technology and Mitsubishi Electric’s industrial robots, with the aim of helping manufacturers achieve agile, variable-volume production and flexible manufacturing for improved productivity in the face of rising capital-investment and labor costs as well as diversifying consumer needs.

As Mitsubishi Electric strives to transform into a “Circular Digital-Engineering Company,” its FA systems business is investing in and cooperating with software companies to strengthen automation and digitalization in diverse manufacturing processes, including design, manufacturing, testing, operation and maintenance, ultimately to provide customers with best-in-class products and solutions.

For the full text, please visit: www.MitsubishiElectric.com/news/

Contacts

Customer Inquiries
Factory Automation Systems Group

Mitsubishi Electric Corporation

www.MitsubishiElectric.com/fa/support/

Media Inquiries
Takeyoshi Komatsu

Public Relations Division

Mitsubishi Electric Corporation

Tel: +81-3-3218-2332

[email protected]
www.MitsubishiElectric.com/news/

- ADVERTISEMENT -
spot_img

Partnered Events

Latest News

Sensorion Announces New Positive Secondary Efficacy Endpoints Data From SENS-401 Phase 2a Clinical Trial For The Preservation Of Residual Hearing Loss

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel...

More Articles Like This